Working Toward A Cure: Janssen’s Multiple Myeloma Strategy

T-cell Engagers, CAR-T Therapy Build On Darzalex Success

Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.

Multiple myeloma concept on tablet screen with stethoscope — Janssen will build on its Darzalex franchise with CAR-T therapies, bispecifics and more • Source: Alamy

Multiple myeloma is all about combination regimens, but Janssen Pharmaceutical Cos. is bringing forward new therapies with promising single-agent activity with the goal of shaking up existing regimens and curing patients early in their disease. Mark Wildgust, vice president of global medical affairs in Janssen’s oncology group, explained to Scrip how the Johnson & Johnson subsidiary is building on its success with the CD38 inhibitor Darzalex (daratumumab) with curative regimens in mind.

Darzalex and its subcutaneously administered version Darzalex Faspro are approved in six different multiple myeloma indications, including as a monotherapy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

20 Jun 2025

• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.